1
|
Yamada A, Akahane D, Takeuchi S, Miyata K, Sato T, Gotoh A. Robot therapy aids mental health in patients with hematological malignancy during hematopoietic stem cell transplantation in a protective isolation unit. Sci Rep 2024; 14:4737. [PMID: 38413634 PMCID: PMC10899246 DOI: 10.1038/s41598-024-54286-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 02/10/2024] [Indexed: 02/29/2024] Open
Abstract
Patients with hematological malignancy experience physical and psychological pain, such as a sense of isolation and confinement due to intensive chemotherapy in a protective isolation unit (PIU). We examined whether the intervention of a robotic puppy, aibo (manufactured by Sony), could improve patients' mental health as an alternative therapy for pet therapy, which is not feasible in PIU. This study included 21 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) (n = 16) or autologous HSCT (n = 5). The patients were randomly divided into the aibo and control groups. Psychological effects were regularly assessed by measuring the levels of salivary stress hormone chromogranin A (CgA), serum oxytocin, and serum cortisol and the quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) scores. The aibo group demonstrated a significant decrease in CgA level, while the control group showed the opposite trend. In addition, changes in serum oxytocin and cortisol levels indicated that aibo helped reduce stress. There was no significant difference in the QIDS-SR scores between the two groups; however, the psychomotor activity in the aibo group improved significantly. These findings suggest that aibo intervention during a stay in a PIU can improve the mental health of patients with hematological malignancies who have undergone HSCT.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
| | - Daigo Akahane
- Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Shiho Takeuchi
- Center for Diversity, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
| | - Kaori Miyata
- Department of Nursing, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
| | - Takako Sato
- Department of Nursing, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
| | - Akihiko Gotoh
- Department of Hematology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| |
Collapse
|
2
|
Yamada A, Takahashi Y, Hirose M, Usami Y, Maruya S, Tamakoshi K. Factors associated with perineal pain on the first postnatal day after vaginal delivery: a cross-sectional study of primiparous women. Nagoya J Med Sci 2024; 86:52-63. [PMID: 38505721 PMCID: PMC10945226 DOI: 10.18999/nagjms.86.1.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 05/08/2023] [Indexed: 03/21/2024]
Abstract
Many women report postpartum perineal pain due to perineal trauma after vaginal delivery. Perineal pain after giving birth declines over time; however, perineal trauma and pain negatively impact on the women's quality of life and their ability to care for their children. The degree of perineal trauma and instrument delivery with episiotomy are associated with perineal pain. Nevertheless, no studies have examined factors related to postpartum perineal pain, including weight changes during pregnancy as well as the course of delivery so far. We aimed to elucidate obstetric factors associated with perineal pain after vaginal delivery on the first postnatal day in Japanese primiparous women. A cross-sectional study conducted in five maternity hospitals in Japan included 142 primiparous women who vaginally delivered full-term and singleton infants. Perineal pain on the first postnatal day was evaluated using a visual analog scale. The final analysis included 92 participants with a mean age of 30.3 ± 4.6 years. The median visual analog scale score was 54.0 mm. Multiple linear regression analysis demonstrated that gestational weight gain above the recommended Japanese range was positively and significantly associated with perineal pain on the first postnatal day, independent of maternal age, episiotomy, painkiller use, and neonatal birth weight. This finding may provide additional evidence regarding gestational weight gain within the recommended range based on the pre-pregnancy body mass index to reduce perineal pain on the first postnatal day.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuki Takahashi
- Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masami Hirose
- Faculty of Health Science and Nursing, Juntendo University, Shizuoka, Japan
| | - Yurika Usami
- Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Saho Maruya
- Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Koji Tamakoshi
- Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
3
|
Yamada A, Wake K, Imaoka S, Motoyoshi M, Yamamoto T, Asano M. Analysis of the effects of importin α1 on the nuclear translocation of IL-1α in HeLa cells. Sci Rep 2024; 14:1322. [PMID: 38225348 PMCID: PMC10789739 DOI: 10.1038/s41598-024-51521-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 01/06/2024] [Indexed: 01/17/2024] Open
Abstract
Interleukin-1α (IL-1α), a cytokine released by necrotic cells, causes sterile inflammation. On the other hand, IL-1α is present in the nucleus and also regulates the expression of many proteins. A protein substrate containing a classical nuclear localization signal (cNLS) typically forms a substrate/importin α/β complex, which is subsequently transported to the nucleus. To the best of our knowledge, no study has directly investigated whether IL-1α-which includes cNLS-is imported into the nucleus in an importin α/β-dependent manner. In this study, we noted that all detected importin α subtypes interacted with IL-1α. In HeLa cells, importin α1-mediated nuclear translocation of IL-1α occurred at steady state and was independent of importin β1. Importin α1 not only was engaged in IL-1α nuclear transport but also concurrently functioned as a molecule that regulated IL-1α protein level in the cell. Furthermore, we discussed the underlying mechanism of IL-1α nuclear translocation by importin α1 based on our findings.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Pathology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan.
- Division of Immunology and Pathobiology, Dental Research Center, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan.
| | - Kiyotaka Wake
- Department of Orthodontics, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
- Division of Oral Structural and Functional Biology, Nihon University Graduate School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
| | - Saya Imaoka
- Department of Pathology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
- Division of Immunology and Pathobiology, Dental Research Center, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
| | - Mitsuru Motoyoshi
- Department of Orthodontics, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
- Division of Clinical Research, Dental Research Center, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
| | - Takenori Yamamoto
- Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima, 770-8503, Japan
| | - Masatake Asano
- Department of Pathology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
- Division of Immunology and Pathobiology, Dental Research Center, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8310, Japan
| |
Collapse
|
4
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
5
|
Maruya S, Tamakoshi K, Hirose M, Takahashi Y, Yamada A, Kato N. Modification of the association between nausea and vomiting of pregnancy and anxiety by personality trait during early pregnancy: A longitudinal study of Japanese pregnant women. Jpn J Nurs Sci 2024; 21:e12565. [PMID: 37789679 DOI: 10.1111/jjns.12565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 08/31/2023] [Accepted: 09/04/2023] [Indexed: 10/05/2023]
Abstract
AIM This study aimed to elucidate whether personality traits modify the relationship between nausea and vomiting of pregnancy (NVP) and anxiety, stratified by three pregnancy periods: 5-8 weeks, 9-12 weeks, and 13-20 weeks. METHODS This longitudinal study was conducted from August 2018 to February 2019 at a perinatal outpatient unit in a general hospital. We included 153 pregnant women aged ≥20 years and under 20 weeks of gestation at their first prenatal visit. They completed the Index of Nausea, Vomiting, and Retching, and the State-Trait Anxiety Inventory (STAI) to measure anxiety in terms of both trait (STAI-T) and state anxiety (STAI-S), and retook them at follow-up checkups for a maximum of three times. RESULTS Using longitudinal data until 20 weeks' gestation, changes in NVP and trait anxiety were significantly associated with changes in state anxiety independently, with trait anxiety being more strongly involved than the change in NVP. This tendency was pronounced in the high-trait anxiety group with STAI-T scores of ≥45. Cross-sectional analyses by gestational week showed similar results in the low-trait anxiety group (STAI-T < 45). In the high-trait anxiety group, only trait anxiety was significantly associated with state anxiety up to 12 weeks gestation. However, only NVP was significantly associated with state anxiety after 13 weeks. CONCLUSIONS Pregnant women who tend to be anxious temperamentally may have other factors that cause anxiety besides nausea immediately after the discovery of pregnancy. Understanding personality traits may help reduce anxiety in pregnant women.
Collapse
Affiliation(s)
- Saho Maruya
- Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Koji Tamakoshi
- Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masami Hirose
- Faculty of Health Science and Nursing, Juntendo University, Mishima, Japan
| | - Yuki Takahashi
- Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Akiko Yamada
- Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Noriko Kato
- Department of Obstetrics and Gynecology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
| |
Collapse
|
6
|
Osone K, Katagiri S, Arai Y, Yamada A, Suguro T, Akahane D, Furuya N, Fujimoto H, Ono M, Gotoh A. [Ovarian hyperstimulation syndrome with controlled ovarian stimulation after induction therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Rinsho Ketsueki 2024; 65:69-73. [PMID: 38448000 DOI: 10.11406/rinketsu.65.69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
Abstract
A 27-year-old woman with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia received induction therapy with dasatinib and prednisolone. From the time of diagnosis, oocyte storage was planned in accordance with the patient's wishes. After progesterone administration for suppression of menstruation, and blood cell recovery, ovarian stimulation was performed and a sufficient number of eggs was collected. The patient was considered at high risk for ovarian stimulation syndrome (OHSS) and received cabergoline and letrozole. However, ovarian enlargement and ascites were observed on ultrasonography 2 days after egg collection, and a diagnosis of moderate OHSS was made. Circulatory management was performed and low-molecular-weight heparin was administered. Dasatinib was discontinued due to the appearance of pleural effusion. Fluid retention improved after menstruation resumed, and the patient was able to continue consolidation with dasatinib and cord blood transplantation. Although tyrosine kinase inhibitors are expected to simplify planning of oocyte storage, the risk of complicating OHSS should be noted.
Collapse
Affiliation(s)
- Kai Osone
- Department of Hematology, Tokyo Medical University
| | | | - Yuya Arai
- Department of Hematology, Tokyo Medical University
| | - Akiko Yamada
- Department of Hematology, Tokyo Medical University
| | | | | | | | | | - Masanori Ono
- Department of Obstetrics and Gynecology, Tokyo Medical University
| | | |
Collapse
|
7
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
8
|
Yamada A, Watanabe A, Yamamoto T. Regulatory mechanisms of mitochondrial calcium uptake by the calcium uniporter complex. Biophys Physicobiol 2023; 20:e200004. [DOI: 10.2142/biophysico.bppb-v20.0004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 01/17/2023] [Indexed: 01/19/2023] Open
Affiliation(s)
- Akiko Yamada
- Department of Pathology, Nihon University School of Dentistry
| | - Akira Watanabe
- Institute for Genome Research, Faculty of Pharmaceutical Sciences, Tokushima University
| | - Takenori Yamamoto
- Institute for Genome Research, Faculty of Pharmaceutical Sciences, Tokushima University
| |
Collapse
|
9
|
Yamauchi Y, Yamada A, Kojima T. Glycaemic management in a child with ornithine transcarbamylase deficiency undergoing cardiac surgery with hypothermic cardiopulmonary bypass. Anaesth Rep 2022; 10:e12179. [PMID: 35874323 PMCID: PMC9299967 DOI: 10.1002/anr3.12179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2022] [Indexed: 07/22/2023] Open
Abstract
There is a lack of evidence regarding the optimal intra-operative glycaemic level of patients with ornithine transcarbamylase deficiency to prevent cerebral oedema due to protein catabolism and hyperammonemia. We describe a case of a two-year-old girl with ornithine transcarbamylase deficiency who underwent cardiac surgery requiring cardiopulmonary bypass. A high-dose dextrose infusion to prevent protein catabolism was given throughout surgery, which caused uncontrollable hyperglycaemia unresponsive to high-dose insulin administration. Factors contributing to the hyperglycaemia may have included surgical stress, steroid administration and hypothermia. During invasive surgery, anaesthetists should carefully adjust the rates of dextrose and insulin infusions, guided by close monitoring of blood ammonia, glucose and lactate.
Collapse
Affiliation(s)
- Y. Yamauchi
- Department of AnaesthesiologyAichi Children's Health and Medical CenterAichiJapan
| | - A. Yamada
- Department of AnaesthesiologyAichi Children's Health and Medical CenterAichiJapan
| | - T. Kojima
- Department of AnaesthesiologyAichi Children's Health and Medical CenterAichiJapan
| |
Collapse
|
10
|
Mashima Y, Tamura T, Kunikata J, Tada S, Yamada A, Tanigawa M, Hayakawa A, Tanabe H, Yokoi H. Using Natural Language Processing Techniques to Detect Adverse Events From Progress Notes Due to Chemotherapy. Cancer Inform 2022; 21:11769351221085064. [PMID: 35342285 PMCID: PMC8943584 DOI: 10.1177/11769351221085064] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 02/05/2022] [Indexed: 11/17/2022] Open
Abstract
Objective: In recent years, natural language processing (NLP) techniques have progressed, and their application in the medical field has been tested. However, the use of NLP to detect symptoms from medical progress notes written in Japanese, remains limited. We aimed to detect 2 gastrointestinal symptoms that interfere with the continuation of chemotherapy—nausea/vomiting and diarrhea—from progress notes using NLP, and then to analyze factors affecting NLP. Materials and methods: In this study, 200 patients were randomly selected from 5277 patients who received intravenous injections of cytotoxic anticancer drugs at Kagawa University Hospital, Japan, between January 2011 and December 2018. We aimed to detect the first occurrence of nausea/vomiting (Group A) and diarrhea (Group B) using NLP. The NLP performance was evaluated by the concordance with a review of the physicians’ progress notes used as the gold standard. Results: Both groups showed high concordance: 83.5% (95% confidence interval [CI] 74.1-90.1) in Group A and 97.7% (95% CI 91.3-99.9) in Group B. However, the concordance was significantly better in Group B ( P = .0027). There were significantly more misdetection cases in Group A than in Group B (15.3% in Group A; 1.2% in Group B, P = .0012) due to negative findings or past history. Conclusion: We detected occurrences of nausea/vomiting and diarrhea accurately using NLP. However, there were more misdetection cases in Group A due to negative findings or past history, which may have been influenced by the physicians’ more frequent documentation of nausea/vomiting.
Collapse
Affiliation(s)
- Yukinori Mashima
- Clinical Research Support Center, Kagawa University Hospital, Kagawa, Japan
- Department of Medical Informatics, Kagawa University Hospital, Kagawa, Japan
| | - Takashi Tamura
- Pharmacoepidemiology & PMS Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Jun Kunikata
- Clinical Research Support Center, Kagawa University Hospital, Kagawa, Japan
| | - Shinobu Tada
- Information Network Administration Office, Faculty of Medicine, Kagawa University, Kagawa, Japan
| | - Akiko Yamada
- Department of Medical Informatics, Kagawa University Hospital, Kagawa, Japan
| | - Masatoshi Tanigawa
- Department of Medical Informatics, Kagawa University Hospital, Kagawa, Japan
| | - Akiko Hayakawa
- Pharmacoepidemiology & PMS Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Hirokazu Tanabe
- Pharmacoepidemiology & PMS Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan
| | - Hideto Yokoi
- Clinical Research Support Center, Kagawa University Hospital, Kagawa, Japan
- Department of Medical Informatics, Kagawa University Hospital, Kagawa, Japan
- Information Network Administration Office, Faculty of Medicine, Kagawa University, Kagawa, Japan
| |
Collapse
|
11
|
Watanabe A, Maeda K, Nara A, Hashida M, Ozono M, Nakao A, Yamada A, Shinohara Y, Yamamoto T. Quantitative analysis of mitochondrial calcium uniporter (MCU) and essential MCU regulator (EMRE) in mitochondria from mouse tissues and HeLa cells. FEBS Open Bio 2022; 12:811-826. [PMID: 35060355 PMCID: PMC8972046 DOI: 10.1002/2211-5463.13371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Revised: 11/27/2021] [Accepted: 01/19/2022] [Indexed: 11/18/2022] Open
Abstract
Mitochondrial calcium homeostasis plays critical roles in cell survival and aerobic metabolism in eukaryotes. The calcium uniporter is a highly selective calcium ion channel consisting of several subunits. Mitochondrial calcium uniporter (MCU) and essential MCU regulator (EMRE) are core subunits of the calcium uniporter required for calcium uptake activity in the mitochondria. Recent 3D structure analysis of the MCU‐EMRE complex reconstituted in nanodiscs revealed that the human MCU exists as a tetramer forming a channel pore, with EMRE bound to each MCU at a 1 : 1 ratio. However, the stoichiometry of MCU and EMRE in the mitochondria has not yet been investigated. We here quantitatively examined the protein levels of MCU and EMRE in the mitochondria from mouse tissues by using characterized antibodies and standard proteins. Unexpectedly, the number of EMRE molecules was lower than that of MCU; moreover, the ratios between MCU and EMRE were significantly different among tissues. Statistical calculations based on our findings suggest that a MCU tetramer binding to 4 EMREs may exist, but at low levels in the mitochondrial inner membrane. In brain mitochondria, the majority of MCU tetramers bind to 2 EMREs; in mitochondria in liver, kidney, and heart, MCU tetramers bind to 1 EMRE; and in kidney and heart, almost half of MCU tetramers bound to no EMRE. We propose here a novel stoichiometric model of the MCU‐EMRE complex in mitochondria.
Collapse
Affiliation(s)
- Akira Watanabe
- Division of Molecular Target and Gene Therapy Products National Institute of Health Sciences 3‐25‐26, Tonomachi, Kawasaki‐ku, Kawasaki‐shi Kanagawa 210‐9501 Japan
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Kousuke Maeda
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Atsushi Nara
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Mei Hashida
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Mizune Ozono
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Ayaka Nakao
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Akiko Yamada
- School of Dentistry Nihon University 1‐8‐13, Kanda‐Surugadai, Chiyoda‐ku Tokyo 101‐8310 Japan
| | - Yasuo Shinohara
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
- Faculty of Pharmaceutical Sciences Tokushima University Shomachi‐1 Tokushima 770‐8505 Japan
| | - Takenori Yamamoto
- Division of Molecular Target and Gene Therapy Products National Institute of Health Sciences 3‐25‐26, Tonomachi, Kawasaki‐ku, Kawasaki‐shi Kanagawa 210‐9501 Japan
- Institute for Genome Research Tokushima University Kuramotocho‐3 Tokushima 770‐8503 Japan
| |
Collapse
|
12
|
Suto A, Katagiri S, Akahane D, Ohtuki S, Yamada A, Suguro T, Asano M, Yoshizawa S, Tanaka Y, Furuya N, Okabe S, Fujimoto H, Gotoh M, Gotoh A. [Desquamative esophagitis associated with unrelated allogeneic peripheral blood stem cell transplantation using the FBM conditioning regimen]. Rinsho Ketsueki 2022; 63:83-88. [PMID: 35264506 DOI: 10.11406/rinketsu.63.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Desquamative esophagitis (DE) is a rare benign condition characterized by sheet-like shedding of esophageal squamous epithelial tissue. Although cases of drug-induced DE, such as those induced by direct oral anticoagulants, have been reported, cases of DE complicated with hematopoietic stem cell transplantation (HSCT) are rare. We herein report the case of a 52-year-old woman with FLT3-ITD mutation-positive acute myeloid leukemia who presented with DE immediately after HSCT. Allogeneic peripheral blood HSCT with FBM (fludarabine 180 mg/m2, busulfan 12.8 mg/m2, and melphalan 80 mg/m2) was performed during the first remission. Tacrolimus plus short-term methotrexate was planned for graft-versus-host disease prevention. Common Terminology Criteria for Adverse Events grade 3 equivalent vomiting was observed during treatment with the conditioning regimen. On day 5 after HSCT, a white band of 10 cm in length and 1 cm in width was discharged from the oral cavity during vomiting. Upper gastrointestinal endoscopy revealed mucosal detachment in the entire esophagus and the diagnosis of DE was made. DE improved on providing conservative treatment. We concluded that the mechanical pressure that developed on the esophagus due to frequent vomiting contributed to the mucosal detachment owing to regimen-related toxicity. Even in the FBM regimen, which is widely used as a conditioning regimen, caution is required to prevent DE.
Collapse
Affiliation(s)
- Arisa Suto
- Department of Hematology, Tokyo Medical University
| | | | | | | | - Akiko Yamada
- Department of Hematology, Tokyo Medical University
| | | | | | | | - Yuko Tanaka
- Department of Hematology, Tokyo Medical University
| | | | | | | | | | | |
Collapse
|
13
|
Chiba Y, Yoshizaki K, Tian T, Miyazaki K, Martin D, Saito K, Yamada A, Fukumoto S. Integration of Single-Cell RNA- and CAGE-seq Reveals Tooth-Enriched Genes. J Dent Res 2021; 101:220345211049785. [PMID: 34806461 PMCID: PMC9052834 DOI: 10.1177/00220345211049785] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Organ development is dictated by the regulation of genes preferentially expressed in tissues or cell types. Gene expression profiling and identification of specific genes in organs can provide insights into organogenesis. Therefore, genome-wide analysis is a powerful tool for clarifying the mechanisms of development during organogenesis as well as tooth development. Single-cell RNA sequencing (scRNA-seq) is a suitable tool for unraveling the gene expression profile of dental cells. Using scRNA-seq, we can obtain a large pool of information on gene expression; however, identification of functional genes, which are key molecules for tooth development, via this approach remains challenging. In the present study, we performed cap analysis of gene expression sequence (CAGE-seq) using mouse tooth germ to identify the genes preferentially expressed in teeth. The CAGE-seq counts short reads at the 5'-end of transcripts; therefore, this method can quantify the amount of transcripts without bias related to the transcript length. We hypothesized that this CAGE data set would be of great help for further understanding a gene expression profile through scRNA-seq. We aimed to identify the important genes involved in tooth development via bioinformatics analyses, using a combination of scRNA-seq and CAGE-seq. We obtained the scRNA-seq data set of 12,212 cells from postnatal day 1 mouse molars and the CAGE-seq data set from postnatal day 1 molars. scRNA-seq analysis revealed the spatiotemporal expression of cell type-specific genes, and CAGE-seq helped determine whether these genes are preferentially expressed in tooth or ubiquitously. Furthermore, we identified candidate genes as novel tooth-enriched and dental cell type-specific markers. Our results show that the integration of scRNA-seq and CAGE-seq highlights the genes important for tooth development among numerous gene expression profiles. These findings should contribute to resolving the mechanism of tooth development and establishing the basis for tooth regeneration in the future.
Collapse
Affiliation(s)
- Y. Chiba
- Section of Oral Medicine for
Children, Division of Oral Health, Growth and Development, Faculty of Dental
Science, Kyushu University, Fukuoka, Japan
| | - K. Yoshizaki
- Section of Orthodontics and
Dentofacial Orthopedics, Division of Oral Health, Growth and Development,
Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - T. Tian
- Section of Orthodontics and
Dentofacial Orthopedics, Division of Oral Health, Growth and Development,
Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - K. Miyazaki
- Section of Orthodontics and
Dentofacial Orthopedics, Division of Oral Health, Growth and Development,
Faculty of Dental Science, Kyushu University, Fukuoka, Japan
| | - D. Martin
- Genomics and Computational
Biology Core, National Institute on Deafness and Other Communication
Disorders, National Institute of Dental and Craniofacial Research, National
Institutes of Health, Bethesda, MD, USA
| | - Genomics and Computational Biology Core
- Genomics and Computational
Biology Core, National Institute on Deafness and Other Communication
Disorders, National Institute of Dental and Craniofacial Research, National
Institutes of Health, Bethesda, MD, USA
| | - K. Saito
- Division of Pediatric Dentistry,
Department of Community Social Dentistry, Graduate School of Dentistry,
Tohoku University, Sendai, Japan
| | - A. Yamada
- Division of Pediatric Dentistry,
Department of Community Social Dentistry, Graduate School of Dentistry,
Tohoku University, Sendai, Japan
| | - S. Fukumoto
- Section of Oral Medicine for
Children, Division of Oral Health, Growth and Development, Faculty of Dental
Science, Kyushu University, Fukuoka, Japan
- Division of Pediatric Dentistry,
Department of Community Social Dentistry, Graduate School of Dentistry,
Tohoku University, Sendai, Japan
| |
Collapse
|
14
|
Nguyen N, Yamada A, Naka S, Tani T. Zero-ischemic and sutureless partial nephrectomy by using microwave surgical device: Initial results in canine models. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)01220-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
15
|
Notake T, Shimizu A, Kubota K, Ikehara T, Hayashi H, Yasukawa K, Kobayashi A, Yamada A, Fujinaga Y, Soejima Y. Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy. BJS Open 2021; 5:6319789. [PMID: 34254117 PMCID: PMC8275880 DOI: 10.1093/bjsopen/zraa048] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 11/06/2020] [Indexed: 12/19/2022] Open
Abstract
Background Functional assessment of the future liver remnant (FLR) after major hepatectomy is essential but often difficult in patients with biliary malignancy, owing to obstructive jaundice and portal vein embolization. This study evaluated whether a novel index using gadoxetate disodium-enhanced MRI (EOB-MRI) could predict posthepatectomy liver failure (PHLF) after major hepatectomy for biliary malignancy. Methods The remnant hepatocellular uptake index (rHUI) was calculated in patients undergoing EOB-MRI before major hepatectomy for biliary malignancy. Receiver operating characteristic (ROC) curve analyses were used to evaluate the accuracy of rHUI for predicting PHLF grade B or C, according to International Study Group of Liver Surgery criteria. Multivariable logistic regression analyses comprised stepwise selection of parameters, including rHUI and other conventional indices. Results This study included 67 patients. The rHUI accurately predicted PHLF (area under the curve (AUC) 0.896). A cut-off value for rHUI of less than 0.410 predicted all patients who developed grade B or C PHLF. In multivariable analysis, only rHUI was an independent risk factor for grade B or C PHLF (odds ratio 2.0 × 103, 95 per cent c.i. 19.6 to 3.8 × 107; P < 0.001). In patients who underwent preoperative portal vein embolization, rHUI accurately predicted PHLF (AUC 0.885), whereas other conventional indices, such as the plasma disappearance rate of indocyanine green of the FLR and FLR volume, did not. Conclusion The rHUI is potentially a useful predictor of PHLF after major hepatectomy for biliary malignancy.
Collapse
Affiliation(s)
- T Notake
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - A Shimizu
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Kubota
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Ikehara
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - H Hayashi
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Yasukawa
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - A Kobayashi
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| | - A Yamada
- Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Fujinaga
- Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Soejima
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Paediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
16
|
Yamada A, Araki Y, Tanaka Y, Otsuki S, Yamada A, Moriyama M, Katagiri S, Suguro T, Asano M, Yoshizawa S, Akahane D, Furuya N, Fujimoto H, Okabe S, Gotoh M, Suzuki K, Saito K, Gotoh A. Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study. PLoS One 2021; 16:e0253025. [PMID: 34242226 PMCID: PMC8270139 DOI: 10.1371/journal.pone.0253025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 05/26/2021] [Indexed: 12/14/2022] Open
Abstract
Accurate staging and evaluation of therapeutic effects are important in managing plasma-cell neoplasms. Diffusion-weighted imaging with body signal suppression magnetic resonance imaging (DWIBS-MRI) allows for acquisition of whole-body volumetric data without radiation exposure. This study aimed to investigate the usefulness of DWIBS-MRI in plasma-cell neoplasms. We retrospectively analyzed 29 and 8 Japanese patients with multiple myeloma and monoclonal gammopathy of undetermined significance, respectively, who underwent DWIBS-MRI. We conducted a histogram analysis of apparent diffusion coefficient values. The correlations between each histogram parameter and staging, cell maturation, prognosis, and treatment response were evaluated. We found that the apparent diffusion coefficient values in patients with monoclonal gammopathy of undetermined significance were lower than those in patients with multiple myeloma. Pretreatment apparent diffusion coefficient values of immature myeloma were lower than those of mature myeloma. Moreover, these values decreased in proportion to stage progression in Durie-Salmon classification system but showed no significant correlation with other staging systems or prognosis. Patients were stratified as responder, stable, and non-responder based on the International Myeloma Working Group criteria. The magnitude of changes in apparent diffusion coefficients differed significantly between responders and non-responders (0.154 ± 0.386 ×10–3 mm2/s vs. -0.307 ± 0.424 ×10–3 mm2/s, p = 0.003). Although its usefulness has yet to be established, DWIBS-MRI combined with apparent diffusion coefficient measurement allowed for excellent response evaluation in patients with multiple myeloma. Furthermore, apparent diffusion coefficient analysis using DWIBS-MRI may be useful in predicting cell maturation and total tumor volume.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
- * E-mail:
| | - Yoichi Araki
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - Yuko Tanaka
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Shunsuke Otsuki
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Arisa Yamada
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Mitsuru Moriyama
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | | | - Tamiko Suguro
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Michiyo Asano
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | | | - Daigo Akahane
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Nahoko Furuya
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Hiroaki Fujimoto
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Seiichi Okabe
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Moritaka Gotoh
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Kunihito Suzuki
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - Kazuhiro Saito
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - Akihiko Gotoh
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
17
|
Kato A, Fujishima K, Takami K, Inoue N, Takase N, Suzuki N, Suzuki K, Kuwayama S, Yamada A, Sakai K, Horita R, Nozaki M, Yoshida M, Hirano Y, Yasukawa T, Ogura Y. Remote screening of diabetic retinopathy using ultra-widefield retinal imaging. Diabetes Res Clin Pract 2021; 177:108902. [PMID: 34102247 DOI: 10.1016/j.diabres.2021.108902] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 05/15/2021] [Accepted: 06/02/2021] [Indexed: 10/21/2022]
Abstract
AIMS To study the possibility of constructing a remote interpretation system for retinal images. METHODS An ultra-widefield (UWF) retinal imaging device was installed in the internal medicine department specializing in diabetes to obtain fundus images of patients with diabetes. Remote interpretation was conducted at Nagoya City University using a cloud server. The medical data, severity of retinopathy, and frequency of ophthalmologic visits were analyzed. RESULTS Four hundred ninety-nine patients (mean age, 62.5 ± 13.4 years) were included. The duration of diabetes in 240 (48.1%) patients was less than 10 years and 433 (86.7%) patients had a hemoglobin (Hb) A1c below 8%. Regarding the retinopathy severity, 360 (72.1%) patients had no diabetic retinopathy (NDR), 63 (12.6%) mild nonproliferative retinopathy (NPDR), 38 (7.64%) moderate NPDR, 13 (2.6%) severe NPDR, and 25 (5.0%) PDR. Two hundred forty-one (48.3%) patients had an ophthalmologic consultation within 1 year, 104 (20.8%) had no history of an ophthalmologic consultation. DR was not present in 86 (82.7%) patients who had never had an ophthalmologic examination, 30 (78.9%) patients with severe NPDR or PDR had had an ophthalmologic visit within 1 year. The frequency of ophthalmic visits was correlated negatively with age, diabetes duration, HbA1c, and severity of retinopathy. CONCLUSION Remote interpretation of DR using UWF retinal imaging was useful for retinopathy screening. During the COVID-19 pandemic, a remote screening system that can ensure compulsory social distancing and reduce the number of ophthalmic visits can be a safe system for patients and clinicians.
Collapse
Affiliation(s)
- Aki Kato
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | | | - Kazuhisa Takami
- Kizawa Memorial Hospital, 590 Shimokobi, Kobi-cho, Minokamo, Gifu 505-8503, Japan.
| | - Naomi Inoue
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Noriaki Takase
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Norihiro Suzuki
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Katsuya Suzuki
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Soichiro Kuwayama
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Akiko Yamada
- Kizawa Memorial Hospital, 590 Shimokobi, Kobi-cho, Minokamo, Gifu 505-8503, Japan.
| | - Katsuhisa Sakai
- Kizawa Memorial Hospital, 590 Shimokobi, Kobi-cho, Minokamo, Gifu 505-8503, Japan.
| | - Ryosuke Horita
- Kizawa Memorial Hospital, 590 Shimokobi, Kobi-cho, Minokamo, Gifu 505-8503, Japan.
| | - Miho Nozaki
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Munenori Yoshida
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Yoshio Hirano
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Tsutomu Yasukawa
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| | - Yuichiro Ogura
- Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
| |
Collapse
|
18
|
Ishida H, Nakazawa K, Yanagihara A, Umesaki T, Taguchi R, Yamada A, Nitanda H, Sakaguchi H. Chylothorax associated with lymphatic reflux in a thoracic duct tributary after lung cancer surgery. Thorac Cancer 2021; 12:2221-2224. [PMID: 34152082 PMCID: PMC8327699 DOI: 10.1111/1759-7714.14062] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 06/05/2021] [Accepted: 06/09/2021] [Indexed: 12/25/2022] Open
Abstract
Chyle leaks are attributed to damage to the thoracic duct itself or its tributaries during surgery. Chylothorax after lung cancer surgery can occur due to damaged thoracic duct tributaries; however, little is known of the mechanism involved. A 71-year-old female underwent a left upper lobectomy with hilar and mediastinal lymphadenectomy for a 1.8-cm primary squamous cell carcinoma, and developed a chylothorax a day later. Catheter lymphangiography revealed high-flow chyle leaks from a damaged thoracic duct tributary, known as a bronchomediastinal lymph trunk, due to a lymphatic reflex from the thoracic duct. Subsequently, catheter embolization of the tributary repaired the chylothorax. The potential for persistent chylothorax after lung cancer surgery and successful lymphatic intervention should be noted.
Collapse
Affiliation(s)
- Hironori Ishida
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Ken Nakazawa
- Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Akitoshi Yanagihara
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Tetsuya Umesaki
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Ryo Taguchi
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Akiko Yamada
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Hiroyuki Nitanda
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Hirozo Sakaguchi
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| |
Collapse
|
19
|
Katagiri S, Akahane D, Inukai T, Otsuki S, Yamada A, Moriyama M, Yamada A, Asano M, Yoshizawa S, Tanaka Y, Furuya N, Fujimoto H, Gotoh M, Nakamura S, Gotoh A. Elevation of HHV-6 viral load mimicking HHV-6 reactivation after second umbilical cord blood transplantation in chromosomally integrated human herpesvirus-6. J Infect Chemother 2021; 27:1517-1519. [PMID: 34083146 DOI: 10.1016/j.jiac.2021.05.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2021] [Revised: 05/13/2021] [Accepted: 05/19/2021] [Indexed: 10/21/2022]
Abstract
Human herpesvirus-6 (HHV-6) reactivation is an important complication in patients receiving umbilical cord blood transplantation (CBT). Chromosomally integrated human herpesvirus-6 (ciHHV-6) is a condition in which the complete HHV-6 genome is integrated into the host germline genome and is transmitted in a Mendelian manner. The influence of ciHHV-6 in recipients or donors in cases of CBT is unknown. We report the first case with ciHHV-6 that received CBT twice for acute lymphoblastic T-cell leukemia. HHV-6 DNA in peripheral blood leukocytes (PBLs) was examined over time through two CBTs. After the first CBT, the HHV-6 viral load was significantly reduced by conversion to PBLs derived from the first donor. During the second CBT, an increase in HHV-6 DNA in PBLs and plasma were observed. However, HHV-6 mRNA was not detected in either the sample before 2nd CBT or at the time of HHV-6 DNA elevation. It is considered that the HHV-6 DNA detected in PBLs and plasma samples might be the HHV-6 genome released due to tissue damage. This case suggests that physicians should be aware of HHV-6 DNA variability during allogeneic hematopoietic stem cell transplantation in ciHHV-6 patients.
Collapse
Affiliation(s)
| | - Daigo Akahane
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Tatsuya Inukai
- Department of Microbiology, Tokyo Medical University, Tokyo, Japan
| | - Shunsuke Otsuki
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Arisa Yamada
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Mitsuru Moriyama
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Akiko Yamada
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Michiyo Asano
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | | | - Yuko Tanaka
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Nahoko Furuya
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Hiroaki Fujimoto
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Moritaka Gotoh
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| | - Shigeki Nakamura
- Department of Microbiology, Tokyo Medical University, Tokyo, Japan
| | - Akihiko Gotoh
- Department of Hematology, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
20
|
Yamada A, Katagiri S, Moriyama M, Asano M, Suguro T, Yoshizawa S, Akahane D, Tanaka Y, Furuya N, Fujimoto H, Gotoh M, Aota Y, Nakamura N, Gotoh A. Epstein-Barr virus-associated post-transplant lymphoproliferative disease during dasatinib treatment occurred 10 years after umbilical cord blood transplantation. J Infect Chemother 2021; 27:1076-1079. [PMID: 33518401 DOI: 10.1016/j.jiac.2021.01.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 01/12/2021] [Accepted: 01/16/2021] [Indexed: 11/15/2022]
Abstract
Post-transplant lymphoproliferative disease (PTLD) is defined as a lymphoma that occurs after solid-organ or hematopoietic stem-cell transplantation (HSCT), caused by immunosuppression and Epstein-Barr virus (EBV) reactivation. It is an important post-transplant complication that can be fatal. After HSCT, most PTLD occurs within 2 years. Recent evidence suggests that tyrosine kinase inhibitors (TKIs) are expected to be effective maintenance therapy after HSCT for Philadelphia chromosome-positive leukemia. However, it is unclear whether the use of TKIs might pose a risk of developing PTLD after HSCT. We present the first case of late-onset PTLD during dasatinib treatment, which occurred 10 years after umbilical cord blood transplantation (CBT). A 59-year-old man who received CBT for chronic myeloid leukemia blast phase needed long-term dasatinib therapy for molecular relapse. Ten years after CBT, he developed diffuse-large B-cell lymphoma (DLBCL). We observed chimerism of the DLBCL sample, which indicated complete donor type and EBV-DNA, and the patient was diagnosed with PTLD. Because of treatment resistance, he died 6 months after PTLD onset. Although he received no long-term administration of immunosuppressive agents, he received long-term dasatinib treatment, which suggests that prolonged dasatinib use after CBT caused EBV reactivation and led to PTLD. Our case suggests that the potential contribution of molecular-targeted agents after HSCT to the development of PTLD should be carefully considered.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Hematology, Tokyo Medical University, Japan.
| | | | | | - Michiyo Asano
- Department of Hematology, Tokyo Medical University, Japan
| | - Tamiko Suguro
- Department of Hematology, Tokyo Medical University, Japan
| | | | - Daigo Akahane
- Department of Hematology, Tokyo Medical University, Japan
| | - Yuko Tanaka
- Department of Hematology, Tokyo Medical University, Japan
| | - Nahoko Furuya
- Department of Hematology, Tokyo Medical University, Japan
| | | | - Moritaka Gotoh
- Department of Hematology, Tokyo Medical University, Japan
| | - Yasuo Aota
- Department of Hematology, Tokyo Medical University, Japan; Department of Internal Medicine, Kohsei Chuo General Hospital, Japan
| | - Naoya Nakamura
- Department of Pathology, Tokai University School of Medicine, Japan
| | - Akihiko Gotoh
- Department of Hematology, Tokyo Medical University, Japan
| |
Collapse
|
21
|
Ishii J, Takahashi H, Nishimura H, Fujiwara W, Ohta M, Kawai H, Muramatsu T, Harada M, Yamada A, Naruse H, Motoyama S, Watanabe E, Izawa H, Ozaki Y. Circulating presepsin (soluble CD14 subtype) as a novel marker of mortality in patients treated at medical cardiac intensive care units. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Presepsin, a subtype of soluble CD14, is an inflammatory marker, which largely reflects monocyte activation. The association between presepsin levels and mortality in patients treated at medical cardiac intensive care units (CICUs) remains poorly known.
Objective
We aimed to understand the prognostic value of presepsin levels on admission to medical CICUs for mortality.
Methods
We prospectively studied 1636 heterogeneous patients (median age; 71 years) treated at medical (non-surgical) CICUs. Patients with stage 5 chronic kidney disease (estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2) were excluded. Acute coronary syndrome was present in 46% of the patients, and acute decompensated heart failure in 36%. Upon admission, baseline plasma presepsin levels were measured. The primary endpoint was all-cause death.
Results
During a mean follow-up period of 44.6 months after admission, there were 323 (19.7%) deaths. Patients who died were older (median: 75 vs. 71 years, P<0.0001); had higher levels of presepsin (194 vs. 110 pg/mL, P<0.0001), B-type natriuretic peptide (BNP: 520 vs. 144 pg/mL, P<0.0001), high-sensitivity C-reactive protein (hsCRP: 4.7 vs. 2.0 mg/L, P<0.0001), and sequential organ failure assessment (SOFA) score (3 vs. 2, P<0.0001); and had lower levels of eGFR (55 vs. 69 mL/min/1.73m2, P<0.0001) and left ventricular ejection fraction (46% vs. 52%, P<0.0001) than those of the survivors. Multivariate Cox regression analyses revealed presepsin levels as independent predictors of all-cause deaths when assessed as either continuous variables (relative risk [RR] 3.33 per 10-fold increment; P<0.0001) or variables categorized according to quartiles (RR quartile 4 vs. 1, 3.60; P<0.0001). Quartiles of presepsin levels were significantly (P<0.0001) associated with increased risk of mortality (Figure). Adding presepsin levels to a baseline model that included established risk factors, BNP, and hsCRP further enhanced reclassification (P=0.009) and discrimination (P=0.0008) beyond that of the baseline model alone.
Conclusions
Circulating concentration of presepsin on admission may be a potent and independent predictor of mortality, and it may improve the risk stratification of patients admitted at medical CICUs.
Presepsin quartiles and mortality
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- J Ishii
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Takahashi
- Division of Statistics, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Nishimura
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - W Fujiwara
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - M Ohta
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Kawai
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Muramatsu
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Harada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - A Yamada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Naruse
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - S Motoyama
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - E Watanabe
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Izawa
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - Y Ozaki
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| |
Collapse
|
22
|
Moriyama M, Yoshizawa S, Fujimoto H, Akahane D, Suguro T, Yamada A, Machida M, Inoue R, Morishima Y, Gotoh A. [Persistent malnutrition caused by Nihonkaiense diphyllobothriasis diagnosed during treatment of malignant lymphoma]. Rinsho Ketsueki 2020; 61:750-752. [PMID: 32759561 DOI: 10.11406/rinketsu.61.750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 72-year-old man with ileocecal lymphadenopathy was found to have Epstein-Barr virus-positive diffuse large B-cell lymphoma using open biopsy, and an ileostoma was created. R-CHOP-like chemotherapy was initiated, but his malnutrition did not improve. After 3 cycles of chemotherapy, a 2-m-long Cestoda was removed from the stoma and was identified as Diphyllobothrium nihonkaiense using mitochondria cytochrome c oxidase subunit 1 targeted polymerase chain reaction analysis. Although D. nihonkaiense infections are asymptomatic, the ileostomy was thought to have exacerbated the malabsorption in this patient. Parasitic infections are rare; however, they should be added to the differential diagnosis of malnutrition of unknown cause during chemotherapy for hematological malignancies.
Collapse
Affiliation(s)
| | | | | | | | | | - Akiko Yamada
- Department of Hematology, Tokyo Medical University
| | | | - Rie Inoue
- Department of Pathology, Tokyo Medical University
| | | | | |
Collapse
|
23
|
Hirose M, Tamakoshi K, Takahashi Y, Mizuno T, Yamada A, Kato N. The effects of nausea, vomiting, and social support on health-related quality of life during early pregnancy: A prospective cohort study. J Psychosom Res 2020; 136:110168. [PMID: 32593093 DOI: 10.1016/j.jpsychores.2020.110168] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 06/02/2020] [Accepted: 06/04/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To date, no previous study has examined the independent association between nausea, vomiting, and social support and health-related quality of life among early pregnant women. METHODS To fill this gap, we investigated these associations within this group using repeated-measurement data. METHODS A prospective cohort design was conducted from August 2018 to February 2019 with perinatal outpatients in a general hospital. Participants were 153 pregnant women aged 20 years or older and under 20 weeks of gestation at their first prenatal visit. Along with reporting their sociodemographic data, participants completed the Index of Nausea, Vomiting, and Retching (INVR), the 12-item Short Form Health Survey (SF-12), and the Multidimensional Scale of Perceived Social Support (MSPSS) and re-completed INVR, and SF-12 at follow-up checkups a maximum of three times. RESULTS After controlling for internal correlations and confounding factors, INVR was found to be significantly negatively associated with the physical component summary scale score of SF-12; however, MSPSS showed no association with the physical component summary scale score. Conversely, the scores for both INVR and MSPSS were negatively and positively, respectively, significantly associated with the mental component summary scale score of SF-12. CONCLUSION The severity of nausea and vomiting significantly impacts physical quality of life during early pregnancy. Both nausea and vomiting and social support significantly and independently affect mental quality of life. Health professionals should recognize these impacts and be aware that social support contributes to improving mental quality of life.
Collapse
Affiliation(s)
- Masami Hirose
- Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya City, Aichi 461-8673, Japan.
| | - Koji Tamakoshi
- Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya City, Aichi 461-8673, Japan.
| | - Yuki Takahashi
- Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya City, Aichi 461-8673, Japan.
| | - Taeko Mizuno
- Department of Nursing, NIHON FUKUSHI University, 229 KawaMinamishinden, Ota-Machi, Tokai-City, Aichi 477-3295, Japan.
| | - Akiko Yamada
- Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya City, Aichi 461-8673, Japan.
| | - Noriko Kato
- Department of Obstetrics and Gynecology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myokencho, Showa-ku, Nagoya City, Aichi 466-8650, Japan.
| |
Collapse
|
24
|
Takajo I, Iwao C, Aratake M, Nakayama Y, Yamada A, Takeda N, Saeki Y, Umeki K, Toyama T, Hirabara Y, Fukuda M, Okayama A. Pseudo-outbreak of Mycobacterium paragordonae in a hospital: possible role of the aerator/rectifier connected to the faucet of the water supply system. J Hosp Infect 2020; 104:545-551. [DOI: 10.1016/j.jhin.2019.11.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 11/20/2019] [Accepted: 11/20/2019] [Indexed: 10/25/2022]
|
25
|
ITANO A, Kitamura S, Tato W, Yamada A, Tasaki H, Katsuhiko M. SUN-280 Predictive factors for dialysis induction and life prognosis in patients who have introduced CRRT in our hospital. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
26
|
Ubara Y, Hara S, Katori H, Arizono K, Ikeguti H, Yokoyama K, Hinosita F, Inoue S, Kuzuhara K, Yamada A, Mimura N. Acute Pancreatitis in a Capd Patient in Association with Hemolytic Anemia. Perit Dial Int 2020. [DOI: 10.1177/089686089701700123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Y. Ubara
- Department of Interna Medicine1, Tokyo, Japan
| | - S. Hara
- Department of Interna Medicine1, Tokyo, Japan
| | - H. Katori
- Department of Interna Medicine1, Tokyo, Japan
| | - K. Arizono
- Department of Interna Medicine1, Tokyo, Japan
| | - H. Ikeguti
- Department of Interna Medicine1, Tokyo, Japan
| | - K. Yokoyama
- Department of Interna Medicine1, Tokyo, Japan
| | - F. Hinosita
- Department of Interna Medicine1, Tokyo, Japan
| | - S. Inoue
- Department of Surgery Toranomon Hospital Kidney Center Minatoku, Tokyo, Japan
| | - K. Kuzuhara
- Department of Surgery Toranomon Hospital Kidney Center Minatoku, Tokyo, Japan
| | - A. Yamada
- Department of Interna Medicine1, Tokyo, Japan
| | - N. Mimura
- Department of Interna Medicine1, Tokyo, Japan
| |
Collapse
|
27
|
Izumida E, Suzawa T, Miyamoto Y, Yamada A, Otsu M, Saito T, Yamaguchi T, Nishimura K, Ohtaka M, Nakanishi M, Yoshimura K, Sasa K, Takimoto R, Uyama R, Shirota T, Maki K, Kamijo R. Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption. J Dent Res 2020; 99:429-436. [PMID: 31986066 DOI: 10.1177/0022034520901731] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood. We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification. Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration. PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R. To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation. When differentiated into osteoblastic-lineage cells, PFE-iPSCs showed no abnormality in mineralization. The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2. Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs. In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts. Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
Collapse
Affiliation(s)
- E Izumida
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - T Suzawa
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - Y Miyamoto
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - A Yamada
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - M Otsu
- Stem Cell Bank & Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Present address: Department of Transfusion and Cell Transplantation, School of Medicine, Kitasato University, Sagamihara, Japan
| | - T Saito
- Division of Tissue Engineering, Department of Bone and Cartilage Regenerative Medicine, University of Tokyo Hospital, The University of Tokyo, Tokyo, Japan
| | - T Yamaguchi
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - K Nishimura
- Laboratory for Gene Regulation, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - M Ohtaka
- TOKIWA-Bio, Inc., Tsukuba, Japan
| | - M Nakanishi
- Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan
| | - K Yoshimura
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - K Sasa
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - R Takimoto
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
- Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan
| | - R Uyama
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - T Shirota
- Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan
| | - K Maki
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - R Kamijo
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| |
Collapse
|
28
|
Kawada Y, Yamada A, Hoshino N, Hoshino M, Yamabe S, Takada K, Sakaguchi E, Ozaki Y. P251 Right ventricular free wall dissection clearly detected and recorded by echocardiography: a fatal complication after inferior myocardial infarction. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
An 81-year-old man was transferred to our institution by ambulance because of poor feeding, general fatigue and slight disorientation lasting for a week. On arrival, he was awake and able to speak, however, his blood pressure was low at 61/43 mmHg in spite of his medical history of hypertension. His ECG showed abnormal Q waves and ST elevation in II, III, aVF leads. The echo exam detected severe hypokinesis in the left ventricular inferior wall and reduced ejection fraction at 30%. Pericardial effusion was not observed in the first echo exam. The patient was diagnosed as cardiogenic shock due to recent inferior myocardial infarction. Coronary angiography was performed, which detected total occlusion of mid right coronary artery, followed by a successful percutaneous coronary intervention (PCI) with a drug-eluting stent under the support of intra-aortic balloon pumping. Nevertheless, his blood pressure remained low and intravenous adrenaline administration was necessary during and even after PCI. To detect the cause of prolonged low blood pressure, echo was performed again immediately after PCI. The echo exam detected new findings: right ventricular posterior free wall was dissected and abnormal shunt flows were obviously observed from left ventricle to right atrium through the dissection cavity during systole. An urgent surgical repair was considered as the only option for his survival, however, his family did not accept it because the operation itself was too risky. On the next day of his admission, he passed away. Right ventricular free wall dissection is a very rare but fatal complication after inferior myocardial infarction, nevertheless, we could detect it by echocardiography with clearly recorded images.
Abstract P251 Figure.
Collapse
Affiliation(s)
- Y Kawada
- Fujita Health University School of Medicine, Toyoake, Japan
| | - A Yamada
- Fujita Health University School of Medicine, Toyoake, Japan
| | - N Hoshino
- Fujita Health University School of Medicine, Toyoake, Japan
| | - M Hoshino
- Fujita Health University School of Medicine, Toyoake, Japan
| | - S Yamabe
- Fujita Health University School of Medicine, Toyoake, Japan
| | - K Takada
- Fujita Health University School of Medicine, Toyoake, Japan
| | - E Sakaguchi
- Fujita Health University School of Medicine, Toyoake, Japan
| | - Y Ozaki
- Fujita Health University School of Medicine, Toyoake, Japan
| |
Collapse
|
29
|
Nakamura K, Yamada A, Kato M, Jinno S, Takahashi A, Sugimoto K, Sugimoto K, Ishikawa T, Ozaki Y, Ishii J. P1512 Combination of mitral annular peak systolic and early diastolic velocities with early transmitral peak flow velocity: a new prognostic echo index in patients with acute coronary syndrome. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
One of the novel echocardiographic indices reflecting left ventricular (LV) diastolic filling is the combination of mitral annular peak systolic (s’) and early diastolic velocities (e’) with early transmitral peak flow velocity (E); E/(e’ x s’). This index is reported to be useful to predict a prognosis of heart failure patients regardless of their LV ejection fraction (LVEF).Purpose: The aim of this study was to examine whether or not E/(e’ x s’) could predict cardiac events in patients with acute coronary syndrome (ACS).Methods: We studies consecutive ACS patients hospitalized in our institution between December 2009 and February 2012. They underwent echo examination within 7 days after admission. By use of Doppler tissue imaging, e’ and s’ were respectively calculated by averaging the peak velocities measured at both septal and lateral mitral annulus in 4-chamber view. The exclusion criteria were as follows: atrial fibrillation, significant valvular diseases and inadequate echo images. Cardiac events were defined as re-hospitalization due to recurrent ACS and/or heart failure, and cardiac mortality.Results: In total, 168 patients were eligible for this study (mean age 67 ± 11 years, mean LVEF 51.7 ± 10.3 %). Median follow-up period was 22.5 months. During the follow-up, cardiac events occurred in 27 patients (16.1%). Between the patients with cardiac events and those without, there were significant differences in LV end-systolic volume (44.2 ± 29.1 vs 33.2 ± 13.6 ml, p < 0.05), LV mass index (122.4 ± 38.9 vs 107.5 ± 26.4 g/m², p < 0.05), left atrial volume index (31.7 ± 9.2 vs 27.6 ± 9.4 ml/m², p < 0.05), LVEF (45.7 ± 13.5 vs 52.9 ± 9.2 %, p < 0.05), s’ (5.1 ± 1.6 vs 7.1 ± 1.7 cm/sec, p < 0.001), e’ (4.8 ± 1.3 vs 6.0 ± 1.9 cm/sec, p < 0.05), E/e’ (16.4 ± 6.6 vs 12.5 ± 4.9, p < 0.05), E/(e’ x s’) (3.78 ± 2.52 vs 1.94 ± 1.08, p < 0.001), and serum B-type natriuretic peptide (334.7 ± 420.1 vs 113.8 ± 177.2 pg/ml, p < 0.05). While Cox proportional hazard multivariate analysis detected that E/(e’ x s’) and E/e’ were independent predictors of cardiac events, E/(e’ x s’) was more powerful than E/e’ (p = 0.0002 vs p = 0.0072). ROC analysis revealed that 2.35 of E/(e’ x s’) was the optimal cutoff values to predict cardiac events in ACS patients (AUC 0.79). Patients with E/(e’ x s’) <2.35 had significantly better prognosis than the rest (p < 0.0001, Log-rank; Figure)Conclusion: E/(e’ x s’) could be a useful echo marker to predict cardiac events in ACS patients.
Abstract P1512 Figure.
Collapse
Affiliation(s)
- K Nakamura
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - A Yamada
- Fujita Health University, Department of Cardiology, Toyoake, Japan
| | - M Kato
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - S Jinno
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - A Takahashi
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - K Sugimoto
- Fujita Health University, Department of Medical Technology, Toyoake, Japan
| | - K Sugimoto
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - T Ishikawa
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - Y Ozaki
- Fujita Health University, Department of Cardiology, Toyoake, Japan
| | - J Ishii
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| |
Collapse
|
30
|
Nakamura K, Yamada A, Jinno S, Kato M, Takahashi A, Sugimoto K, Sugimoto K, Ishikawa T, Ozaki Y, Ishii J. P1508 Left ventricular diastolic function plays a different role on mortality depending on the severity of systolic dysfunction in acute heart failure patients with reduced ejection fraction. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
It remains to be clarified whether clinical significance of left ventricular (LV) diastolic function differs depending on the severity of LV systolic dysfunction in patients with acute heart failure (AHF). The aim of this study was to examine the prognostic role of LV diastolic function in AHF patients with various systolic dysfunction.Methods: We studied consecutive hospitalized AHF patients with LV ejection fraction (LVEF) <50%. The exclusion criteria were as follows: atrial fibrillation, severe mitral regurgitation, and inadequate echo image quality. They underwent echocardiography on admission. The eligible patients (n = 289, 165 males, 76 ± 10 years) were divided into 4 groups based on LVEF and left atrial pressure (LAP) grade estimated as in the ESC guidelines: Group I (LVEF 40-49% (mildly reduced LVEF)/normal LAP, n = 28), II (mildly reduced EF/increased LAP, n = 38), III (LVEF <40% (severely reduced LVEF)/normal LAP, n = 110), and IV (severely reduced LVEF/increased LAP, n = 113). Cardiac death was examined up to 60 months.Results: In total, 58 patients (20%) died because of cardiac events during the follow-up (mean 20 ± 19 months). In patients with mildly reduced LVEF, Group I showed significantly less cardiac death ratio than II (n = 1 vs 10, Group I vs II, p = 0.03). On the other hand, in patients with severely reduced LVEF, there was no significant difference in cardiac death ratio between Group III and IV (n = 23 vs 24, Group III vs IV, p = 0.80). That is, LAP grade was a prognostic marker when the patients had mild LV systolic dysfunction, whereas it did not contribute to the prediction of cardiac mortality when patients showed severely reduced LV systolic function. Group I showed significantly better prognosis than those with severe LV systolic dysfunction regardless of LAP grade (Group III, IV) (Group I vs III, p = 0.04; Group I vs IV, p = 0.04).Conclusions: LV diastolic function may have a different clinical significance depending on the severity of LV systolic dysfunction in AHF patients.
Collapse
Affiliation(s)
- K Nakamura
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - A Yamada
- Fujita Health University, Department of Cardiology, Toyoake, Japan
| | - S Jinno
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - M Kato
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - A Takahashi
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - K Sugimoto
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - K Sugimoto
- Fujita Health University, Department of Medical Technology, Toyoake, Japan
| | - T Ishikawa
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| | - Y Ozaki
- Fujita Health University, Department of Cardiology, Toyoake, Japan
| | - J Ishii
- Fujita Health University Hospital, Clinical Laboratory, Toyoake, Japan
| |
Collapse
|
31
|
Sakaguchi E, Yamada A, Hoshino M, Takada K, Hoshino N, Kawada Y, Yamabe S, Ozaki Y. P1386 A change in left ventricular global longitudinal strain is a prognostic indicator in congestive heart failure patients with preserved ejection fraction. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purposes
We examined how changes in left ventricular (LV) global longitudinal strain (GLS) were associated with prognosis in patients with preserved LV ejection fraction (LVEF) after congestive heart failure (HF) admission.
Methods
We studied 123 consecutive patients (age 70 ± 15 years, 55% male) who had been hospitalized due to congestive HF with preserved LVEF (> 50%). The exclusion criteria were atrial fibrillation and inadequate echo image quality for strain analyses. The patients underwent speckle-tracking echocardiography and measurement of plasma NT-ProBNP levels on the same day at the time of hospital admission as well as in the stable condition after discharge. Differences in GLS, LVEF and NT-ProBNP (delta GLS, LVEF and NT-ProBNP ; 2nd – 1st measurements) were calculated. The study end points were all-cause mortality and cardiac events.
Results
Mean periods of echo performance after hospitalization were 2 ±1days (1st echo) and 240 ± 289 days (2nd echo), respectively. During the follow-up (974 ± 626 days), 12 patients died and 25 patients were hospitalized because of HF worsening. In multivariate analysis, delta GLS and follow-up GLS were prognostic factors, whereas baseline and follow-up LVEF, NT-ProBNP, changes in LVEF and NT-ProBNP could not predict cardiac events. Delta GLS (p = 0.002) turned out to be the best independent prognosticator. Receiver operating characteristics analysis revealed that -0.6% of delta GLS was the optimal cut-off value to predict cardiac events and mortality (sensitivity 76%, specificity 67%, AUC 0.75). Kaplan-Meier analysis showed that patients with delta GLS more than -0.6% experienced significantly less cardiac events during the follow-up period (p < 0.0001, log-rank).
Conclusion
A change in LV GLS after congestive HF admission was a predictor of the prognosis in patients with preserved LVEF. It would be useful to check the changes in GLS in those with preserved LVEF after discharge.
Collapse
Affiliation(s)
- E Sakaguchi
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - A Yamada
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - M Hoshino
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - K Takada
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - N Hoshino
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - Y Kawada
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - S Yamabe
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| | - Y Ozaki
- Fujita Health University School of Medicine, Cardiology, Toyoake, Japan
| |
Collapse
|
32
|
Yamabe S, Ito R, Sakakibara T, Yamada A, Ohshima S, Ozaki Y. 1043 Association of left ventricular global longitudinal strain with myocardial perfusion evaluated by 13N-ammonia positron emission tomography in hemodialysis patients with preserved ejection fraction. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Global longitudinal strain (GLS) is an echocardiographic marker to detect subclinical left ventricular systolic dysfunction prior to the appearance of reduced left ventricular ejection fraction (LVEF). Reduced GLS identified in patients with maintenance hemodialysis (HD) has been reported to be a predictor of their higher mortality and cardiovascular events. On the other hand, pharmacological stress 13N-ammonia positron emission tomography (13N-NH3-PET) has been an established and reliable imaging modality to evaluate myocardial perfusion expressed as coronary flow reserve (CFR) or maximal stress myocardial blood flow (MBF). CFR and MBF are powerful parameters to detect coronary artery disease and to predict cardiovascular events and mortality. However, association between GLS and those myocardial perfusion parameters are not fully understood.
Purpose:The aim of this study was to evaluate the relationship between GLS and the myocardial perfusion parameters of 13N-NH3-PET in HD patients with preserved LVEF.
Methods
We studied 24 HD patients (mean age 67 years, 67% male) who underwent ATP stress 13N-NH3-PET as well as transthoracic echocardiography including 2-dimensional speckle tracking imaging for suspected ischemic heart disease. Exclusion criteria were as follows: LVEF <50%, moderate to severe valvular diseases, and atrial fibrillation. Myocardial perfusion abnormality (MPA) was defined as CFR <2.0 and/or stress MBF <2.0.
Results
Mean GLS in all patients was -16.2 ± 3.6%. The patients were divided into 2 groups based on GLS: patients with reduced GLS (<-16%) (Group A, N = 11) and those with preserved GLS (≧-16%) (Group B, N = 14). There were no significant differences between 2 groups in age, gender, body mass index, left ventricular mass index, and average E/e’. Nevertheless, Group A had significantly lower stress MBF than Group B (1.7 ± 0.41 vs 2.0 ± 0.33, p = 0.031). In addition, Group A showed more frequent MPA compared with Group B (81.8% vs 42.9%, p = 0.043). There was a moderate correlation between GLS and stress MBF (r = 0.62, p = 0.0012), whereas no significant correlation was noted between GLS and CFR (r = 0.079, p = 0.71).
Conclusion
Reduced GLS was significantly associated MPA. MPA may be one of the major contributors to the reduction in GLS in HD patients with preserved LVEF.
Collapse
Affiliation(s)
- S Yamabe
- Fujita Health University, Toyoake, Japan
| | - R Ito
- Kyoritsu Hospital, Nagoya, Japan
| | | | - A Yamada
- Fujita Health University, Toyoake, Japan
| | | | - Y Ozaki
- Fujita Health University, Toyoake, Japan
| |
Collapse
|
33
|
Otsuka K, Yamada A, Saito M, Ushio A, Sato M, Kisoda S, Shao W, Tsunematsu T, Kudo Y, Arakaki R, Ishimaru N. Achaete-Scute Homologue 2–Regulated Follicular Helper T Cells Promote Autoimmunity in a Murine Model for Sjögren Syndrome. The American Journal of Pathology 2019; 189:2414-2427. [DOI: 10.1016/j.ajpath.2019.08.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 08/12/2019] [Accepted: 08/26/2019] [Indexed: 02/06/2023]
|
34
|
Suekane S, Noguchi M, Terasaki M, Yutani S, Narita Y, Yamada A, Shichijo S, Igawa T, Itoh K. Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Yoshiyama K, Noguchi M, Terasaki M, Sugawara S, Yamada A, Shichijo S, Takamori S, Akagi Y, Yutani S, Itoh K. P2.04-65 Peptide-Based Cancer Vaccine Shortened the Overall Survival of a Large Portion, but Not All, of Advanced Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Sawaki M, Yamada A, Kumamaru H, Miyata H, Shimizu C, Miyashita M, Honma N, Taira N, Saji S. Elderly patients in the Japanese breast cancer registry. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Ishii J, Takahashi H, Nishimura T, Kawai H, Muramatsu T, Harada M, Yamada A, Naruse H, Hayashi M, Motoyama S, Sarai M, Watanabe E, Izawa H, Ozaki Y. P4620Circulating concentration of presepsin improves early prediction of short-term mortality in patients treated at medical cardiac intensive care units. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Presepsin, a subtype of soluble CD14, is an inflammatory marker, which largely reflects monocytic activation. Presepsin appears to be an accurate diagnostic marker of sepsis, but its clinical significance remains unclear in cardiovascular disease.
Purpose
This prospective study aimed to investigate the predictive value of plasma presepsin levels on admission to medical (non-surgical) cardiac intensive care units (MCICUs) for short-term mortality.
Methods
We examined 1560 patients hospitalized in MCICUs and measured the baseline plasma presepsin levels at admission.
Results
Acute coronary syndrome was present in 46% of the patients, and acute decompensated heart failure in 36%. Before MCICUs admission, emergent coronary angiography or percutaneous coronary intervention was performed in 36%, mechanical ventilation was required for respiratory insufficiency in 2.1%, and intraaortic balloon pumps were needed for hemodynamic instability in 8.9%. During 6 months after admission, there were 113 (7.2%) deaths. Patients who died were older (median: 77 vs. 71 years, P<0.0001); had higher levels of presepsin (263 vs. 119 pg/mL, P<0.0001), B-type natriuretic peptide (BNP: 696 vs. 186 pg/mL, P<0.0001), high-sensitivity troponin T (hsTnT: 81 vs. 47 pg/mL, P=0.004), and high-sensitivity C-reactive protein (13.8 vs. 2.2 mg/L, P<0.0001); and had lower levels of estimated glomerular filtration rate (50 vs. 65 mL/min/1.73m2, P<0.0001) and left ventricular ejection fraction (43% vs. 51%, P<0.0001) than those of the survivors. In the multivariate Cox regression analysis, higher levels of presepsin (P=0.0002), BNP (P=0.04), and hsTnT (P=0.009) were all independent predictors of 6-month deaths. Quartiles of presepsin levels were associated with higher mortality rates within 6 months after admission (Table). Adding presepsin levels to a baseline model that included established risk factors, BNP, and hsTnT further enhanced reclassification (P=0.004) and discrimination (P=0.003) beyond that of the baseline model.
Mortality rates according to presepsin Presepsin quartile 1st 2nd 3rd 4th P value ≤80 pg/mL 81–124 pg/mL 125–232 pg/mL >232 pg/mL 1-month mortality 0.8% 2.0% 3.3% 8.0% <0.0001 6-month mortality 0.8% 3.8% 8.2% 16.3% <0.0001
Conclusions
Presepsin levels at admission could improve the prediction of short-term mortality in patients hospitalized at MCICUs.
Collapse
Affiliation(s)
- J Ishii
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Takahashi
- Division of Statistics, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Nishimura
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Kawai
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Muramatsu
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Harada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - A Yamada
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Naruse
- Dept of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Hayashi
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - S Motoyama
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - M Sarai
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - E Watanabe
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| | - H Izawa
- Dept of Cardiology, Banbuntane Hotokukai Hospital, Nagoya, Japan
| | - Y Ozaki
- Dept of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan
| |
Collapse
|
38
|
Yamamoto T, Ozono M, Watanabe A, Maeda K, Nara A, Hashida M, Ido Y, Hiroshima Y, Yamada A, Terada H, Shinohara Y. Functional analysis of coiled-coil domains of MCU in mitochondrial calcium uptake. Biochim Biophys Acta Bioenerg 2019; 1860:148061. [PMID: 31394096 DOI: 10.1016/j.bbabio.2019.148061] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 07/20/2019] [Accepted: 08/02/2019] [Indexed: 11/30/2022]
Abstract
The mitochondrial calcium uniporter (MCU) complex is a highly-selective calcium channel. This complex consists of MCU, mitochondrial calcium uptake proteins (MICUs), MCU regulator 1 (MCUR1), essential MCU regulator element (EMRE), etc. MCU, which is the pore-forming subunit, has 2 highly conserved coiled-coil domains (CC1 and CC2); however, their functional roles are unknown. The yeast expression system of mammalian MCU and EMRE enables precise reconstitution of the properties of the mammalian MCU complex in yeast mitochondria. Using the yeast expression system, we here showed that, when MCU mutant lacking CC1 or CC2 was expressed together with EMRE in yeast, their mitochondrial Ca2+-uptake function was lost. Additionally, point mutations in CC1 or CC2, which were expected to prevent the formation of the coiled coil, also disrupted the Ca2+-uptake function. Thus, it is essential for the Ca2+ uptake function of MCU that the coiled-coil structure be formed in CC1 and CC2. The loss of function of those mutated MCUs was also observed in the mitochondria of a yeast strain lacking the yeast MCUR1 homolog. Also, in the D. discoideum MCU, which has EMRE-independent Ca2+-uptake function, the deletion of either CC1 or CC2 caused the loss of function. These results indicated that the critical functions of CC1 and CC2 were independent of other regulatory subunits such as MCUR1 and EMRE, suggesting that CC1 and CC2 might be essential for pore formation by MCUs themselves. Based on the tetrameric structure of MCU, we discussed the functional roles of the coiled-coil domains of MCU.
Collapse
Affiliation(s)
- Takenori Yamamoto
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan.
| | - Mizune Ozono
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Akira Watanabe
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Kosuke Maeda
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Atsushi Nara
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Mei Hashida
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Yusuke Ido
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Yuka Hiroshima
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan
| | - Akiko Yamada
- School of Dentistry, Tokushima University, Kuramotocho-3, Tokushima 770-8504, Japan
| | - Hiroshi Terada
- Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan
| | - Yasuo Shinohara
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan.
| |
Collapse
|
39
|
Masimbula R, Yamada A, Takahashi K, Matsuura H. Total Synthesis of (8 S) and (8 R) Methyl 8-β- d-Glucopyranosyl-Helianthenate B and Their Application for Other Derivatives. Nat Prod Commun 2019. [DOI: 10.1177/1934578x19861013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The first total synthesis of (8 R) and (8 S) methyl β-d-glucopyranosyl helianthenate B was accomplished using the Cadiot-Chodkiewicz coupling reaction as a key step. Significant differences were observed in the resonances between the 1H-NMR and 13C-NMR spectra of the diastereomers. Based on these results, the absolute configurations of glucopyranosyloxymethine in methyl β-d-glucopyranosyl helianthenate A to E (1 -5) were reconfirmed to be the ( R) configuration.
Collapse
Affiliation(s)
- Rishni Masimbula
- Laboratory of Natural Product Chemistry, Division of Fundamental AgriScience Research, Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan
| | - Akiko Yamada
- Laboratory of Natural Product Chemistry, Division of Fundamental AgriScience Research, Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan
| | - Kosaku Takahashi
- Department of Nutritional Science, Faculty of Applied Bioscience, Tokyo University of Agriculture, Setagaya-ku, Japan
| | - Hideyuki Matsuura
- Laboratory of Natural Product Chemistry, Division of Fundamental AgriScience Research, Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan
| |
Collapse
|
40
|
Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Kawai S, Uenaka N, Sato E, Katsuta E, Kawaguchi T, Takabe K, Ishikawa T. Abstract P1-15-12: Axillary lymph node metastasis and HER2-receptor positivity significantly associate with recurrence and worse survival in breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-15-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND
Neoadjuvant chemotherapy (NAC) has become a common practice in breast cancer care since it not only expands the opportunity for breast conservation surgery, but also allows in vivo assessment of individual cancer biology. Patients who achieved pathological complete response (pCR) after NAC are known to have significantly improved outcomes than those who did not. To date, there has been no large study of factors that associate with tumor recurrence after patients had pCR following NAC. To identify such factors, we examined a cohort of 394 patients.
METHODS
Patients diagnosed during 2007-16 with clinical stage I-III breast cancer who achieved pCR following NAC were identified from clinical records at four hospitals in urban Japan. Nearly 70% of patients received standard NAC regimen, which was a combination of anthracycline and taxane, with trastuzumab added as needed. pCR was defined as no pathological evidence of invasive cancer in the breast; residual ductal carcinoma in situ (DCIS) and residual axillary lymph node metastasis were included in this study. The median follow-up time was 63 months (range = 16-161 months). Outcomes were assessed by 5-year disease-free survival (DFS) and 5-year overall survival (OS).
RESULTS
Among the 394 patients with pCR, the breast cancer subtype was as follows: Luminal – 49 (12.4%), Luminal-HER2 – 97 (24.6%), HER2 – 117 (29.7%), and TNBC – 131 (33.2%). During follow up, 28 (7.1%) of the 394 patients had experienced tumor recurrence. In univariate Cox regression analysis, each of HER2-receptor status, pre-NAC tumor size, and pre-NAC axillary lymph node status were associated with recurrence. The hazard ratios, and their 95% confidence intervals (CI) and P values for these significant factors were as follows. HER2-receptor negative vs. positive: 2.5 (CI = 1.0-5.8; P = 0.036); cT1/2 vs. cT3/4: 2.2 (CI = 1.3-6.1; P = 0.008); cN0 vs. cN1-3: 9.5 (2.2-40.7; P = 0.002). However, age (<50 vs. ≥50 y), residual DCIS, post-NAC axillary lymph node status, type of mastectomy (total vs. partial), and adjuvant radiation therapy were not associated with recurrence. Of the 28 patients with recurrence, site of first event was local for 8, and brain and visceral for 10 each. Seven of the 10 patients with brain metastasis were HER2-receptor positive. Eleven of the 28 patients with recurrence had deceased, with a median post-recurrence survival duration of 40 months (range = 2–94 months). Shorter survival was associated with HER2-receptor positivity (P = 0.003).
CONCLUSION
Axillary lymph node metastasis before rather than after NAC, and HER2-receptor positivity are associated with tumor recurrence in patients who achieved pCR in breast cancer. HER2-receptor positive patients had higher risk for brain metastasis and shorter survival. Given the extreme rarity of local recurrence after pCR, we cannot help but speculate that omitting surgical removal of pCR tissue may be permissible when pCR has been diagnosed accurately.
Citation Format: Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Kawai S, Uenaka N, Sato E, Katsuta E, Kawaguchi T, Takabe K, Ishikawa T. Axillary lymph node metastasis and HER2-receptor positivity significantly associate with recurrence and worse survival in breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-15-12.
Collapse
Affiliation(s)
- M Asaoka
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - K Narui
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - N Suganuma
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - T Chishima
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - A Yamada
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - S Kawai
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - N Uenaka
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - E Sato
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - E Katsuta
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - T Kawaguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - K Takabe
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| | - T Ishikawa
- Tokyo Medical University Hospital, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
| |
Collapse
|
41
|
Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selected therapeutic personalized peptide vaccines (PPV) were effective for boosting anticancer immune response that was associated with the clinical outcome as a prognostic factor for metastatic recurrent breast cancer (mrBC) 1-2. In this study, we investigated the immunological and clinical effect of PPV as the prophylactic cancer vaccine for non-recurrent but high-risk BC (nrhrBC) patients (pts), and we compared it's features to those of the mrBC pts who had active cancers or became resistant to the standard therapies(TR-mrBC). Methods: Material and Patient eligibility criteria: The peptides were selected from the 31 PPVs according to the results of HLA typing and peptide-specific IgG titers. Pts with a histological diagnosis of BC and their HLA-A molecules should be each of -A2, A3, A11, A24, A26, A31 or A33. The clinical protocols were approved by the institutional review board. (UMIN000003081and 00000184400000). Treatment schedule: A maximum of 4 peptides was administrated as weekly for initial four vaccinations and as biweekly for further inoculations. The concomitant standard endocrine therapy and the chemo-endocrine therapy were available for nrhrBC pts after finishing the standard adjuvant chemotherapy, and for mrBC pts concurrently. Immune and clinical response assessment: Specific T-cell responses, IgG titers and cytokines were evaluated using by interferon (IFN)-γ ELISPOT, Luminex assay and ELISA system in every 6-8 vaccinations. Toxicity, clinical response and correlation with the immune responses were investigated. Results: 16 pts with nrhrBC, 41 pts with mrBC and 79 pts with TR-mrBC received median 18, 16 and 14 vaccines, respectively. After PPV therapies, peptide-specific IgG and CTLs increased significantly in a total of 47 (77%) and 37(60%) in nrhrBC pts, 102 (63%) and 98 (61%) in mrBC pts, and 150(53%) and 100 (42%) in TR-mrBC pts. Pts experienced Grade 1-3 skin reaction at injection site, no other grade 3 or 4 SAEs were associated with PPV but with the disease progression or combination therapy. The median time to progression (TTP) and overall survival (OS) were not reached in nrhrBC pts, 7.8 and 29 months in mrBC pts, and were 7.5 and 15.9 months in TR-mrBC pts, respectively. The peptide specific CTL response was correlated significantly with OS in nrhrBC pts and the IgG levels were associated with the better OS in either non TR-mrBC pts or TR-mrBC pts. High levels of IL-6, GM-CSF, IFN-g, IL-2 receptor, BAFF were associated with worse prognosis for pts with TR-mrBC. And high levels of GM-CSF and BAFF were associated with worse prognosis for pts with nrhrBC and mrBC, respectively. In contrast, High levels of IL-2 were associated with the better prognosis for pts with mrBC. Conclusion: This study indicated that immunological features of these three groups were different from each other with most potent PPV-induced immune boosting for nrhrBC pts. Pts with mrBC who had lower immune-suppressive cytokine levels had the better prognosis. These results suggested the PPV therapy could be effective for postoperative prophylactic vaccination in patients with nrhrBC. References: 1. Takahashi R, Toh U, et al. Breast Cancer Res. 2014; 2. Toh U, Okabe M, et al. THE BREAST 2015.
Citation Format: Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-06.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Okabe
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Takao
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Tanaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Shigaki
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Takenaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Sudo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - A Yamada
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - S Shichijo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Akagi
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| |
Collapse
|
42
|
Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Abstract OT1-05-04: Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy ( JONIE4:J-CAT trial). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline and taxan treatment. For such patients, capecitabine seems to be effective to reduce recurrence based on the HR 0.58 of the CREATE X trial (Masuda, N. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 376, 2147. 2017) . However, the target of capecitabine is still unclear for TNBC. We classified non pCR tumors as BRCAness and Sporadic using BRCAness test(MRC-Holland, Amsterdam, the Netherlands). The recurrence rate of the BRCAness group was about 70%. Carboplatine is expected to be effective against BRCAness tumors, as it is a DNA damaging agent. In this study BRCAness can be checked just before carboplatin treatment using surgical specimens. Then the efficacy of carboplatin will be directly known to make comparison between DFS in the carboplatin group and that of the observation group.
Trial design: This is anopen label, randomized phase III study that will enroll TNBC with residual invasive cancer after surgery with preoperative chemotherapy including both anthracycrine and taxan. Patients are randomly assigned to either the carboplatin group or observation group. The patients in the carboplatin group are treated with carboplatin at AUC 6 and those in the observation group are observed at only 3 years.
Eligibility criteria:
1) ER and PgR<1%, HER2 0, 1+ or 2+ with FISH negative on core needle biopsy before the chemotherapy and surgical specimens.
2) Preoperative chemotherapy including both anthracycrine and taxan.
3) Residual invasive cancer on breast tumors or lymph node metastasis in surgical specimens.
4) 20-79 year old women.
5) No chemotherapy within 5 years.
6) Not bilateral breast cancer, without metastasis, no prior breast cancer.
7) No severe bone marrow suppression.
Specific aims:Primary objective is DFS (Disease Free Survival). Secondary objectives are overall survival and safety.
STATISTICAL METHODS:
The 3 years recurrence rate of the observation group was estimated as 40% and hazard ratio at 0.58 based on the CREATE X trial. For both groups, 135 patients are necessary. This study is powered to approximately 80% to test the superiority of carboplatin group at a 2-sided α=0.05 using a stratified log-rank test.
Activation Date:22ndMarch 2018. No patients had been enrolled till 3rd July.
Citation Format: Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-05-04.
Collapse
Affiliation(s)
- H Tanino
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Suzuki
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - H Kaise
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Miyashita
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Chishima
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Hayashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Miyoshi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Futamura
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - S Ohtani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Nagahashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ohta
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Kosaka
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ishikawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Hasegawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Kubota
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Sangai
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Iwatani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - A Yamada
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - K Akazawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - N Kohno
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| |
Collapse
|
43
|
Saito M, Otsuka K, Ushio A, Yamada A, Arakaki R, Kudo Y, Ishimaru N. Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren's Syndrome. Curr Rheumatol Rev 2019; 14:239-245. [PMID: 28124612 PMCID: PMC6225342 DOI: 10.2174/1573397113666170125122858] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 01/13/2017] [Accepted: 01/23/2017] [Indexed: 02/07/2023]
Abstract
Sjogren’s syndrome (SS) is a T cell-mediated autoimmune disease of the systemic exocrine glands, such as salivary and lacrimal glands. A variety of T-cell subpopulations maintain immune tolerance in the thymus and periphery through complex immune responses including cellular and humoral immunity. The T-cell subpopulations exhibiting abnormal or unique phenotypes and impaired functionality have been reported to play important roles in the cellular mechanisms of autoimmunity in SS patients and animal models of SS. In this review, we focused on follicular helper T cells related to antibody production and regulatory T cells to control immune tolerance in the pathogenesis of SS. The unique roles of these T-cell subpopulations in the process of the onset or development of SS have been demonstrated in this review of recent publications. The clinical application of these T-cell subpopulations will be helpful for the development of new techniques for diagnosis or treatment of SS in the future.
Collapse
Affiliation(s)
- Masako Saito
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Kunihiro Otsuka
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Aya Ushio
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Akiko Yamada
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Rieko Arakaki
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Yasusei Kudo
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| | - Naozumi Ishimaru
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan
| |
Collapse
|
44
|
Ushio A, Arakaki R, Otsuka K, Yamada A, Tsunematsu T, Kudo Y, Aota K, Azuma M, Ishimaru N. CCL22-Producing Resident Macrophages Enhance T Cell Response in Sjögren's Syndrome. Front Immunol 2018; 9:2594. [PMID: 30467506 PMCID: PMC6236111 DOI: 10.3389/fimmu.2018.02594] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Accepted: 10/22/2018] [Indexed: 12/28/2022] Open
Abstract
Macrophages (MΦs) are critical regulators of immune response and serve as a link between innate and acquired immunity. The precise mechanism of involvement of tissue-resident MΦs in the pathogenesis of autoimmune diseases is not clear. Here, using a murine model for Sjögren's syndrome (SS), we investigated the role of tissue-resident MΦs in the onset and development of autoimmunity. Two unique populations of CD11bhigh and CD11blow resident MΦs were observed in the target tissue of the SS model. Comprehensive gene expression analysis of chemokines revealed effective production of CCL22 by the CD11bhigh MΦs. CCL22 upregulated the migratory activity of CD4+ T cells by increasing CCR4, a receptor of CCL22, on T cells in the SS model. In addition, CCL22 enhanced IFN-γ production of T cells of the SS model, thereby suggesting that CCL22 may impair the local immune tolerance in the target organ of the SS model. Moreover, administration of anti-CCL22 antibody suppressed autoimmune lesions in the SS model. Finally, histopathological analysis revealed numerous CCL22-producing MΦs in the minor salivary gland tissue specimens of the SS patients. CCL22-producing tissue-resident MΦs may control autoimmune lesions by enhancing T cell response in the SS model. These results suggest that specific chemokines and their receptors may serve as novel therapeutic or diagnostic targets for SS.
Collapse
Affiliation(s)
- Aya Ushio
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Rieko Arakaki
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Kunihiro Otsuka
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Akiko Yamada
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Takaaki Tsunematsu
- Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Yasusei Kudo
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Keiko Aota
- Department of Oral Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Masayuki Azuma
- Department of Oral Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Naozumi Ishimaru
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| |
Collapse
|
45
|
Otsuka K, Yamada K, Taquahashi Y, Arakaki R, Ushio A, Saito M, Yamada A, Tsunematsu T, Kudo Y, Kanno J, Ishimaru N. Long-term polarization of alveolar macrophages to a profibrotic phenotype after inhalation exposure to multi-wall carbon nanotubes. PLoS One 2018; 13:e0205702. [PMID: 30372450 PMCID: PMC6205598 DOI: 10.1371/journal.pone.0205702] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 09/28/2018] [Indexed: 01/23/2023] Open
Abstract
Background Nanomaterials are widely used in various fields. Although the toxicity of carbon nanotubes (CNTs) in pulmonary tissues has been demonstrated, the toxicological effect of CNTs on the immune system in the lung remains unclear. Methods and finding In this study, exposure to Taquann-treated multi-walled CNTs (T-CNTs) was performed using aerosols generated in an inhalation chamber. At 12 months after T-CNT exposure, alveolar inflammation with macrophage accumulation and hypertrophy of the alveolar walls were observed. In addition, fibrotic lesions were enhanced by T-CNT exposure. The macrophages in the bronchoalveolar lavage fluid of T-CNT-exposed mice were not largely shifted to any particular population, and were a mixed phenotype with M1 and M2 polarization. Moreover, the alveolar macrophages of T-CNT-exposed mice produced matrix metalloprotinase-12. Conclusions These results suggest that T-CNT exposure promoted chronic inflammation and fibrotic lesion formation in profibrotic macrophages for prolonged periods.
Collapse
Affiliation(s)
- Kunihiro Otsuka
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Koichi Yamada
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Yuhji Taquahashi
- Division of Cellular and Molecular Toxicology, Biological Safety Research Center, National Institute of Health Sciences, Kanagawa, Japan
| | - Rieko Arakaki
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Aya Ushio
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Masako Saito
- Department of Immunology and Parasitology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Akiko Yamada
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Takaaki Tsunematsu
- Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Yasusei Kudo
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Jun Kanno
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan
| | - Naozumi Ishimaru
- Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
- * E-mail:
| |
Collapse
|
46
|
Uehara S, Sato KK, Koh H, Shibata M, Kinuhata S, Yamada A, Oue K, Kambe H, Morimoto M, Hayashi T. The Association Between Metabolically Healthy Obesity and the Risk of Proteinuria: The Kansai Healthcare Study. J Epidemiol 2018; 28:361-366. [PMID: 29628481 PMCID: PMC6048297 DOI: 10.2188/jea.je20170082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background Metabolically healthy obesity seems to be a unique phenotype for the risk of cardiometabolic diseases. However, it is not known whether this phenotype is associated with the risk of proteinuria. Methods Study subjects were 9,185 non-diabetic Japanese male workers aged 40–55 years who had no proteinuria, an estimated glomerular filtration rate ≥60 mL/min/1.73 m2, no history of cancer, and no use of antihypertensive or lipid-lowering medications at baseline. Obesity was defined as body mass index ≥25.0 kg/m2. Metabolic health was defined as the presence of no Adult Treatment Panel III components of the metabolic syndrome criteria, excluding waist circumference, and metabolic unhealth was defined as the presence of one or more metabolic syndrome components, excluding waist circumference. “Consecutive proteinuria” was considered positive if proteinuria was detected twice consecutively as 1+ or higher on urine dipstick at annual examinations to exclude chance proteinuria as much as possible. Results During the 81,660 person-years follow-up period, we confirmed 390 cases of consecutive proteinuria. Compared with metabolically healthy non-obesity, metabolically healthy obesity was not associated with the risk of consecutive proteinuria (multiple-adjusted hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.37–1.99), but metabolically unhealthy non-obesity with ≥2 metabolic syndrome components (HR 1.77; 95% CI, 1.30–2.42), metabolically unhealthy obesity with one component (HR 1.71; 95% CI, 1.12–2.61), and metabolically unhealthy obesity with ≥2 metabolic syndrome components (HR 2.77; 95% CI, 2.01–3.82) were associated with an increased risk of consecutive proteinuria. Conclusions Metabolically healthy obesity did not increase the risk of consecutive proteinuria in Japanese middle-aged men.
Collapse
Affiliation(s)
- Shinichiro Uehara
- Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine
| | - Kyoko Kogawa Sato
- Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine
| | - Hideo Koh
- Hematology, Osaka City University Graduate School of Medicine
| | - Mikiko Shibata
- Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine
| | - Shigeki Kinuhata
- Medical Education and General Practice, Osaka City University Graduate School of Medicine
| | | | - Keiko Oue
- Kansai Health Administration Center, Nippon Telegraph and Telephone West Corporation
| | - Hiroshi Kambe
- Kansai Health Administration Center, Nippon Telegraph and Telephone West Corporation
| | - Michio Morimoto
- Kansai Health Administration Center, Nippon Telegraph and Telephone West Corporation
| | - Tomoshige Hayashi
- Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine
| |
Collapse
|
47
|
Yamamoto T, Tsunoda M, Ozono M, Watanabe A, Kotake K, Hiroshima Y, Yamada A, Terada H, Shinohara Y. Polyethyleneimine renders mitochondrial membranes permeable by interacting with negatively charged phospholipids in them. Arch Biochem Biophys 2018; 652:9-17. [PMID: 29886045 DOI: 10.1016/j.abb.2018.06.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Revised: 06/05/2018] [Accepted: 06/06/2018] [Indexed: 01/21/2023]
Abstract
Polyethyleneimines (PEIs) are used for transfection of cells with nucleic acids. Meanwhile, the interaction of PEI with mitochondria causes cytochrome c release prior to apoptosis; the mechanisms how PEI causes this permeabilization of mitochondrial membranes and the release of cytochrome c remain unclear. To clarify these mechanisms, we examined the effects of branched-type PEI and linear-type PEI, each of which was 25 kDa in size, on mitochondria. The permeabilization potency of mitochondrial membranes by branched PEI was stronger than that by linear PEI. The permeabilization by PEIs were insensitive to permeability-transition inhibitors, indicating that PEI-induced permeabilization was not attributed to permeability transition. Meanwhile, PEIs caused permeabilization of artificial lipid vesicles; again, the permeabilization potency of branched PEI was stronger than that of linear PEI. Such a difference in this potency was close to that in the case of isolated mitochondria, signifying that the PEI-induced permeabilization of mitochondrial membranes could be attributed to PEI's interaction with the phospholipid phase. Furthermore, this PEI-induced permeabilization of the lipid vesicles was observed only in the case of lipid vesicles including negatively charged phospholipids. These results indicate that PEIs interacted with negatively charged phospholipids in the mitochondrial membranes to directly lead to their permeabilization.
Collapse
Affiliation(s)
- Takenori Yamamoto
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan.
| | - Moe Tsunoda
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Mizune Ozono
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Akira Watanabe
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Kazumasa Kotake
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| | - Yuka Hiroshima
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan
| | - Akiko Yamada
- School of Dentistry, Tokushima University, Kuramotocho-3, Tokushima 770-8504, Japan
| | - Hiroshi Terada
- Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan
| | - Yasuo Shinohara
- Institute for Genome Research, Tokushima University, Kuramotocho-3, Tokushima 770-8503, Japan; Faculty of Pharmaceutical Sciences, Tokushima University, Shomachi-1, Tokushima 770-8505, Japan
| |
Collapse
|
48
|
Abstract
Some food-derived opioid peptides have been reported to cause diseases, such as gastrointestinal inflammation, celiac disease, and mental disorders. Bifidobacterium is a major member of the dominant human gut microbiota, particularly in the gut of infants. In this study, we evaluated the potential of Bifidobacterium in the degradation of food-derived opioid peptides. All strains tested showed some level of dipeptidyl peptidase activity, which is thought to be involved in the degradation of food-derived opioid peptides. However, this activity was higher in bifidobacterial strains that are commonly found in the intestines of human infants, such as Bifidobacterium longum subsp. longum, B. longum subsp. infantis, Bifidobacterium breve and Bifidobacterium bifidum, than in those of other species, such as Bifidobacterium animalis and Bifidobacterium pseudolongum. In addition, some B. longum subsp. infantis and B. bifidum strains showed degradative activity in food-derived opioid peptides such as human and bovine milk-derived casomorphin-7 and wheat gluten-derived gliadorphin-7. A further screening of B. bifidum strains revealed some bifidobacterial strains that could degrade all three peptides. Our results revealed the potential of Bifidobacterium species in the degradation of food-derived opioid peptides, particularly for species commonly found in the intestine of infants. Selected strains of B. longum subsp. infantis and B. bifidum with high degradative capabilities can be used as probiotic microorganisms to eliminate food-derived opioid peptides and contribute to host health.
Collapse
Affiliation(s)
- T Sakurai
- 1 Morinaga Milk Industry Co., Ltd., Frontier Research Department, Next Generation Science Institute, 1-83, 5-Chome, Higashihara, Zama-City, Kanagawa-Pref. 252-8583, Japan
| | - A Yamada
- 2 Morinaga Milk Industry Co., Ltd., Functional Food Ingredients Department, Food Ingredients and Technology Institute, 1-83, 5-Chome, Higashihara, Zama-City, Kanagawa-Pref. 252-8583, Japan
| | - N Hashikura
- 1 Morinaga Milk Industry Co., Ltd., Frontier Research Department, Next Generation Science Institute, 1-83, 5-Chome, Higashihara, Zama-City, Kanagawa-Pref. 252-8583, Japan
| | - T Odamaki
- 1 Morinaga Milk Industry Co., Ltd., Frontier Research Department, Next Generation Science Institute, 1-83, 5-Chome, Higashihara, Zama-City, Kanagawa-Pref. 252-8583, Japan
| | - J-Z Xiao
- 1 Morinaga Milk Industry Co., Ltd., Frontier Research Department, Next Generation Science Institute, 1-83, 5-Chome, Higashihara, Zama-City, Kanagawa-Pref. 252-8583, Japan
| |
Collapse
|
49
|
Yamada A, Fuse M, Aoyagi T, Hosaka H, Toma H, Yanagisawa H. Preventive Equipment for Urinary Incontinence: A Device Employing Lower Abdominal Impendance Changes. Int J Artif Organs 2018. [DOI: 10.1177/039139889401700304] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The object of this work was to develop a monitoring device for measuring the volume of urine in the bladder to signal, in advance, the need to urinate and thus help prevent urinary incontinence. A high-frequency electric current of 50 KHz transmitter was applied to a pair of terminals placed on the surface of a human body. The constant current was 2mA (p-p). A pair of voltage electrodes was placed in the path of the electric current to pick up high-frequency voltage signals. The best position for current electrodes was found to be on the surface of both femoral joints. Positioning the voltage electrode above the bladder on the lower abdomen was most efficient for detecting the volume of urine. New current electrodes sutured onto underpants were fitted on the surface above the femoral joints, which did not shift in the case of movement by the subjects. The reproducibility and stability were remarkably good with this electrode. The alarm level which foretold both maximum storage volume and maximum desire to void was examined. After that, when the alarm level was set within the range of impedance charge, 60% to 70%, the possibility of prediction of urination exists.
Collapse
Affiliation(s)
- A. Yamada
- Health Care Center of Tokyo Science University, Tokyo - Japan
| | - M. Fuse
- Nihon Kohden Corp. R&D, Tokyo - Japan
| | - T. Aoyagi
- Tokyo Women's Medical College Kidney Center, Tokyo - Japan
| | - H. Hosaka
- Nihon Kohden Corp. R&D, Tokyo - Japan
| | - H. Toma
- Tokyo Women's Medical College Kidney Center, Tokyo - Japan
| | - H. Yanagisawa
- Tokyo Women's Medical College Kidney Center, Tokyo - Japan
| |
Collapse
|
50
|
Yamada A, Nagahashi M, Aoyagi T, Huang WC, Lima S, Miyazaki H, Narui K, Ishikawa T, Endo I, Waters MR, Milstien S, Spiegel S, Takabe K. Abstract P5-03-05: Sphingosine-1-phosphate produced by sphingosine kinase 1 and exported via ABCC1 shortens survival of mice and humans with breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-03-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sphingosine-1-phosphate (S1P), a bioactive sphingolipid mediator that is generated by sphingosine kinase 1 (SphK1) when it is phosphorylated (pSphK1) inside cells, has been implicated in regulation of many process important for breast cancer progression. Previously we have shown that S1P is exported out of human breast cancer cells by ATP-binding cassette (ABC) transporter ABCC1, but not by ABCB1, both known multidrug resistance proteins that efflux chemotherapeutic agents. However, the pathological consequences of these events to breast cancer progression and metastasis have not been elucidated. Here, we report that high expression of ABCC1, but not ABCB1, is associated with poor prognosis in breast cancer patients via exporting S1P.
Materials and methods: Microarray based gene expression data of 2509 patients associated with their survival were obtained from METABRIC database. Single gene survival analysis based on expressin of SphK1, and dual ABCC1 or ABCB1 and SphK1 survival analyses were perfomerd. For protein analyses, tissues were obrained from 275 patients with stage 1-3 breast cancers treated in Yokohama City University Medical Center in Japan between 2006 and 2008. The expression of pSphK1 was analyzed by immunohistochemistry and investigate the relationship with clinicopathological findings. For in vitro and in vivo experiments, breast cancer cell lines were transfected by ABCB1, ABCC1 or vector transiently or stably. BALB/c nu/nu mice and BALB/c mice were used for in vivo experiments. S1P was measured by LC-ESI-MS/MS.
Results: SphK1 expression significantly associate with worse overall survival (median survival of 124 months with high SphK1 expression compared to 163 months for patients with low SphK1 expression, p=0.0014). Although patients with high ABCC1 expression had only a slightly worse overall survival of 150 months, those with high levels of both SphK1 and ABCC1 had much worse prognosis with median overall survival of 114 months (p < 0.0068). Such association was not observed with ABCB1 expression. The frequency of strong pSphK1 protein expression was higher in HER2 enrhiched or TNBC than in Luminal. pSphK1 was more prevalent and increased in a larger tumors and in tumors from patients with lymph node metastases. Patients with breast cancers that express both pSphK1 and ABCC1 proteins have significantly shorter disease free survival. Overexpression of ABCC1, but not ABCB1, in human MCF7 and murine 4T1 cells enhanced S1P secretion, proliferation and migration of breast cancer cells. Implantation of breast cancer cells overexpressing ABCC1, but not ABCB1, into the mammary pad markedly enhanced tumor growth, angiogenesis and lymphangiogenesis with concomitant increases in lymph node and lung metastases as well as shorter survival of mice. Interestingly, S1P exported via ABCC1 from breast cancer cells upregulated transcription of SphK1 and its own formation.
Conclusions: Our findings suggest that production and export of S1P via ABCC1, but not ABCB1, is associated with worse overall and disease free survival of breast cancer patients and that S1P axis play a role in aggressive biology of breast cancer progression and metastasis.
Citation Format: Yamada A, Nagahashi M, Aoyagi T, Huang W-C, Lima S, Miyazaki H, Narui K, Ishikawa T, Endo I, Waters MR, Milstien S, Spiegel S, Takabe K. Sphingosine-1-phosphate produced by sphingosine kinase 1 and exported via ABCC1 shortens survival of mice and humans with breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-03-05.
Collapse
Affiliation(s)
- A Yamada
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - M Nagahashi
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - T Aoyagi
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - W-C Huang
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - S Lima
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - H Miyazaki
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - K Narui
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - T Ishikawa
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - I Endo
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - MR Waters
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - S Milstien
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - S Spiegel
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| | - K Takabe
- Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan; Virginia Commonwealth University School of Medicine, Richmond, VA; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University, Tokyo, Japan; Roswell Park Cancer Institute, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences The State University of New Yor, Buffalo, NY
| |
Collapse
|